<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02071810</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-91067-102</org_study_id>
    <nct_id>NCT02071810</nct_id>
  </id_info>
  <brief_title>Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067</brief_title>
  <official_title>A Double-blind, Randomised, Placebo-controlled Study to Evaluate the Tolerability, Pharmacokinetics and Pharmacodynamics of Four Multiple Rising Dose Regimens of BIA 9-1067 in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bial - Portela C S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bial - Portela C S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the tolerability of BIA 9-1067 after multiple rising
      dose regimens of BIA 9-1067.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single centre, double-blind, randomised, placebo-controlled study of four dosage regimens of
      BIA 9-1067 in four groups of healthy male volunteers. In each group, the study will consist
      of an once-daily (o.d.) 8-day multiple-dose period. Progression to the next dose level will
      only occur if the previous dose level was considered to be safe and well tolerated. An
      appropriate interval (will separate the investigation of doses to permit a timely review and
      evaluation of safety data prior to proceeding to a higher dose level.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With at Least One Adverse Event</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Parkinson's Disease (PD)</condition>
  <arm_group>
    <arm_group_label>BIA 9-1067 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIA 9-1067 (OPC, Opicapone) 5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIA 9-1067 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIA 9-1067 (OPC, Opicapone) 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIA 9-1067 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIA 9-1067 (OPC, Opicapone) 20 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIA 9-1067 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIA 9-1067 (OPC, Opicapone) 30 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo, PLC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIA 9-1067</intervention_name>
    <arm_group_label>BIA 9-1067 5 mg</arm_group_label>
    <arm_group_label>BIA 9-1067 10 mg</arm_group_label>
    <arm_group_label>BIA 9-1067 20 mg</arm_group_label>
    <arm_group_label>BIA 9-1067 30 mg</arm_group_label>
    <other_name>OPC, Opicapone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>PLC, Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A signed and dated informed consent form before any study-specific screening procedure
             is performed.

          2. Aged between 18 and 45 years, inclusive.

          3. Healthy as determined by the investigator on the basis of medical history, physical
             examination, clinical laboratory test results, vital signs and digital 12-lead
             electrocardiogram (ECG).

          4. Nonsmoker or smoker of fewer than 10 cigarettes per day as determined by history. Must
             be able to abstain from smoking during the inpatient stay.

        Exclusion Criteria:

          1. Any significant cardiovascular (e.g. hypertension), hepatic, renal, respiratory (e.g.
             childhood asthma), gastrointestinal, endocrine (e.g. diabetes, dyslipidemia),
             immunologic, dermatological, haematological, neurologic, or psychiatric disease.

          2. Acute disease state (e.g., nausea, vomiting, fever, diarrhoea) within 7 days before
             study day 1.

          3. History of drug abuse within 1 year before study day 1.

          4. History of alcoholism within 1 year before day 1. Consumption of more than 50 g of
             ethanol per day (12.5 cL glass of 10° [10%] wine = 12 g; 4 cL of aperitif, 42° [42%]
             whiskey = 17 g; 25 cL glass of 3° [3%] beer = 7.5 g; 25 cL glass of 6° [6%] beer = 15
             g

          5. Have previously received BIA 9-1067.

          6. Positive serologic findings for human immunodeficiency virus (HIV) antibodies,
             hepatitis B surface antigen (HBsAg), and/or hepatitis C virus (HCV) antibodies.

          7. Positive findings of urine drug screen (eg, amphetamines, barbiturates,
             benzodiazepines, cannabinoids, cocaine, methadone, opiates, MDMA
             [3,4-methylenedioxy-methamphetamine; ecstasy]).

          8. History of any clinically important drug allergy.

          9. Prohibited Treatments: use of any investigational drug within 90 days or prescription
             drug within 30 days before investigational medical product (IMP) administration.

         10. Consumption of any caffeine-containing products (e.g., coffee, tea, chocolate, or
             soda) in excess of 6 cups per day (or equivalent), of grapefruit,
             grapefruit-containing products, or alcoholic beverages within 24 before study day 1.

         11. Use of any over-the-counter drugs including herbal supplements (except for the
             occasional use of acetaminophen [paracetamol], aspirin and vitamins ≤100% recommended
             daily allowance) within 7 days before IMP administration.

         12. Donation of blood (ie 450 ml) within 90 days before study day 1.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dikran Mouradian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BIOTRIAL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BIOTRIAL</name>
      <address>
        <city>Rueil</city>
        <state>Malmaison</state>
        <zip>F-92501</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2012</study_first_submitted>
  <study_first_submitted_qc>February 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2014</study_first_posted>
  <results_first_submitted>December 30, 2014</results_first_submitted>
  <results_first_submitted_qc>December 30, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 9, 2015</results_first_posted>
  <last_update_submitted>November 23, 2015</last_update_submitted>
  <last_update_submitted_qc>November 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's disease (PD)</keyword>
  <keyword>Opicapone</keyword>
  <keyword>Bial</keyword>
  <keyword>BIA 9-1067</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opicapone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BIA 9-1067 5 mg</title>
          <description>BIA 9-1067 (OPC, Opicapone) 5 mg
BIA 9-1067</description>
        </group>
        <group group_id="P2">
          <title>BIA 9-1067 10 mg</title>
          <description>BIA 9-1067 (OPC, Opicapone) 10 mg
BIA 9-1067</description>
        </group>
        <group group_id="P3">
          <title>BIA 9-1067 20 mg</title>
          <description>BIA 9-1067 (OPC, Opicapone) 20 mg
BIA 9-1067</description>
        </group>
        <group group_id="P4">
          <title>BIA 9-1067 30 mg</title>
          <description>BIA 9-1067 (OPC, Opicapone) 30 mg
BIA 9-1067</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Placebo, PLC
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BIA 9-1067 5 mg</title>
          <description>BIA 9-1067 (OPC, Opicapone) 5 mg
BIA 9-1067</description>
        </group>
        <group group_id="B2">
          <title>BIA 9-1067 10 mg</title>
          <description>BIA 9-1067 (OPC, Opicapone) 10 mg
BIA 9-1067</description>
        </group>
        <group group_id="B3">
          <title>BIA 9-1067 20 mg</title>
          <description>BIA 9-1067 (OPC, Opicapone) 20 mg
BIA 9-1067</description>
        </group>
        <group group_id="B4">
          <title>BIA 9-1067 30 mg</title>
          <description>BIA 9-1067 (OPC, Opicapone) 30 mg
BIA 9-1067</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Placebo, PLC
Placebo</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="7"/>
            <count group_id="B5" value="9"/>
            <count group_id="B6" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With at Least One Adverse Event</title>
        <time_frame>participants will be followed for the duration of hospital stay, an expected average of 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BIA 9-1067 5 mg</title>
            <description>BIA 9-1067 (OPC, Opicapone) 5 mg
BIA 9-1067</description>
          </group>
          <group group_id="O2">
            <title>BIA 9-1067 10 mg</title>
            <description>BIA 9-1067 (OPC, Opicapone) 10 mg
BIA 9-1067</description>
          </group>
          <group group_id="O3">
            <title>BIA 9-1067 20 mg</title>
            <description>BIA 9-1067 (OPC, Opicapone) 20 mg
BIA 9-1067</description>
          </group>
          <group group_id="O4">
            <title>BIA 9-1067 30 mg</title>
            <description>BIA 9-1067 (OPC, Opicapone) 30 mg
BIA 9-1067</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo, PLC
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With at Least One Adverse Event</title>
          <units>Number of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>BIA 9-1067 5 mg</title>
          <description>BIA 9-1067 (OPC, Opicapone) 5 mg
BIA 9-1067</description>
        </group>
        <group group_id="E2">
          <title>BIA 9-1067 10 mg</title>
          <description>BIA 9-1067 (OPC, Opicapone) 10 mg
BIA 9-1067</description>
        </group>
        <group group_id="E3">
          <title>BIA 9-1067 20 mg</title>
          <description>BIA 9-1067 (OPC, Opicapone) 20 mg
BIA 9-1067</description>
        </group>
        <group group_id="E4">
          <title>BIA 9-1067 30 mg</title>
          <description>BIA 9-1067 (OPC, Opicapone) 30 mg
BIA 9-1067</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Placebo, PLC
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Left hemiparesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Research</name_or_title>
      <organization>Bial – Portela &amp; Cª, S.A.</organization>
      <phone>+351 229 866 100</phone>
      <email>jose.rocha@bial.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

